Latest Conference Articles

Findings highlighted that increased physical activity was associated with a variety of benefits in improving overall well-being in early adolescent and young adult survivors.

Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.

Danielle Fournier, DNP, APRN, AGPCNP-BC, AOCNP, discusses the role of oncology nurses in genomic testing.

“When discussing treatment options with patients, it is important to consider efficacy, safety, and the impact of treatment on patients’ quality of life [QOL]…,” noted Brenda Martone, RN, APP.

Nurse practitioners should listen to patients’ concerns and be ready with questions when it comes to germline testing, according to an expert.

Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.

Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.

In accordance with CMS quality measures, interventions like provider/patient education and better access to care help reduce ED visits after chemotherapy.

Oncology nurses and APPs can enhance patients’ comfort by counseling patients on what integrative care is and working to make those options accessible.

Using risk assessment and nurse education in the High ED/Admission Risk Therapy (HEART) protocol reduced ED visits by 18% after chemoradiation treatment.

The 2025 Extraordinary Healer® Award was presented during the 50th Annual Oncology Nursing Society Congress, recognizing oncology nursing professionals' dedication and impact.

Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time with each patient to provide the best care.

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world findings.

Patient-reported outcomes were consistent between patients with RCC using tivozanib/nivolumab and tivozanib monotherapy according to study findings.

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.

Proactive onco-coaching did not improve QOL but was associated with improved OS in patients with metastatic renal cell carcinoma receiving TKIs and ICIs.

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.

Men with intermediate-risk prostate cancer and high PSA levels before HIFU treatment had a greater risk of both overall recurrence and treatment failure.

Enfortumab vedotin alone and in combination with pembrolizumab showed promise in patients with upper tract urothelial carcinoma, particularly those ineligible for standard chemotherapy.

Real-world data demonstrate significant outcome improvements with enfortumab vedotin in patients with unresectable or metastatic urothelial carcinoma.

Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, discontinuation rates were low across all groups.